glp 1 and kidney Potential renoprotective effects of GLP1 receptor agonists. The ICYMI: GLP-1 Agonists Show Promise

Catalase is an important antioxidant produced by RBC

The dose depends on the formulation: 1.4 mg daily for Egrifta SV, 1.28 mg daily for Egrifta WR, or 2 mg daily for research vials (matching the original Phase III trial dose)

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System

I have not lost weight it could be too soon

Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data

New Level II HCPCS Codes Final Rule Comment Solicitation Consistent with past practice, we are soliciting comments on the new Level II HCPCS codes that will be effective January 1, 2026, in the CY 2026 OPPS/ASC final rule with comment period, thereby allowing us to finalize the status indicators and APC assignments for the codes in the CY 2027 OPPS/ASC final rule with comment period